NEW YORK (GenomeWeb) – GenomeDx Biosciences announced today that it has signed an exclusive deal with Medison Pharma to distribute its Decipher Prostate Cancer Classifier in Israel and the Palestinian Authority.

Specific terms of the arrangement were not disclosed.

Decipher is a genomic, RNA expression-based test that predicts cancer aggressiveness with an assay of 22 validated biomarkers associated with metastatic disease. Developed by GenomeDx in collaboration with the Mayo Clinic, the test was first launched in the US in 2013.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.